Auto injectors are utilized for epinephrine self-administration in order to prevent anaphylaxis, for immediate pain relief by migraine sufferers and for medical and emergency treatments. The rise in incidence of anaphylaxis is escalating the growth of auto injectors market.
Frequently Asked Questions
The market is segmented based on Segmentation, By Therapy (Rheumatoid Arthritis, Multiple Sclerosis, Diabetes, Anaphylaxis, Other Therapies), Type (Disposable Auto injectors, Reusable Auto Injectors), End- User (Home Care Settings, Hospitals and Clinics, Ambulatory Surgical Centers), Route of administration (Subcutaneous, Intramuscular), Type of Molecule (Monoclonal Antibody, Peptide, Protein, and Small Molecule), Design (Standardized, Customized), Product (Prefilled, Fillable) – Industry Trends and Forecast to 2031
.
The Global Auto Injectors Market size was valued at USD 83.05 USD Billion in 2023.
The Global Auto Injectors Market is projected to grow at a CAGR of 21.77% during the forecast period of 2024 to 2031.
The major players operating in the market include AbbVie , Mylan N.V., Lily, Amgen , Ypsomed Holding, BD, Owen Mumford , Consort Medical Plc., SHL Medical AG, Johnson Medtech LLC., Teva Pharmaceuticals USA , Antares Pharma., AstraZeneca, Union Medico , Gerresheimer AG, West Pharmaceutical Services , Emergent-.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
